Resources from the same session
LBA34 - Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)
Presenter: Richard Finn
Session: Proffered Paper session 1: GI, upper digestive
Resources:
Abstract
Slides
Webcast
LBA35 - Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
Presenter: Shukui Qin
Session: Proffered Paper session 1: GI, upper digestive
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 1: GI, upper digestive
Resources:
Webcast
LBA36 - Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma
Presenter: Masatoshi Kudo
Session: Proffered Paper session 1: GI, upper digestive
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA36
Presenter: Lam Chan
Session: Proffered Paper session 1: GI, upper digestive
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session 1: GI, upper digestive
Resources:
Webcast